MedTrace Logo

Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL

NCT06468943 · Status: ENROLLING_BY_INVITATION · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-06-21

No results posted yet for this study

Summary

Aim of this study will evaluate the efficacy and safety of Polatuzumab Vedotin and Zanubrutinib in combination with R-CHP for newly diagnosed untreated Non-GCB DLBCL Patients with extranodal involvement.

Conditions

  • Effects of Chemotherapy
  • Safety Issues

Interventions

DRUG

Polatuzumab Vedotin

1.8mg/kg/21d（d0） Intravenous infusion

DRUG

Zanubrutinib

160mg bid PO（d0-d20）

DRUG

Rituximab

375mg/㎡/21d（d0） Intravenous infusion

DRUG

Cyclophosphamide

750mg/㎡/21d（d1） Intravenous infusion

DRUG

Doxorubicin

50mg/㎡/21d（d1） Intravenous infusion

DRUG

Prednisone

100mg PO （d1-d5）/21d

Sponsors & Collaborators

  • The First Affiliated Hospital of Soochow University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-01
Primary Completion
2026-05-01
Completion
2028-05-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06468943 on ClinicalTrials.gov